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Background: In patients with non-severe hemophilia A, we lack detailed knowledge 
on the timing of treatment with factor VIII (FVIII) concentrates. This knowledge could 
provide information about the expected treatment timing in patients with severe he-
mophilia A treated with non-replacement therapies.
Objective: To assess the FVIII treatment history in patients with non-severe hemophilia A.
Methods: Patients with non-severe hemophilia (baseline FVIII activity [FVIII:C] 
2-40 IU/dL) were included from the INSIGHT study. The primary outcome was me-
dian age at first FVIII exposure (ED1). In a subgroup of patients for whom more de-
tailed information was available, we analyzed the secondary outcomes: median age 
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1  | INTRODUC TION
Hemophilia A is an X-linked inherited bleeding disorder, caused by a 
mutation in the F8 gene, leading to a deficiency of functional clotting 
factor VIII (FVIII). The severity of disease is classified according to 
the amount of residual FVIII activity.1,2
In patients with non-severe hemophilia A (FVIII activity 2-40 IU/
dL), bleeding is elicited by trauma or surgery. Therefore, treatment 
is given on demand in order to treat or to prevent these provoked 
bleeds.3 A review of treatment burden in non-severe hemophilia A 
identified 44% of subjects requiring hemostatic treatment at least 
once in a 2-year observation period. In 69% of the patients, treat-
ment consisted of FVIII concentrate.4
In contrast to non-severe hemophilia A, patients with severe he-
mophilia A (FVIII activity < 1.0 IU/dL) experience spontaneous joint 
and muscle bleeds. To prevent chronic joint damage, children with 
severe hemophilia A are treated prophylactically with regular intrave-
nous FVIII infusions.5,6
To reduce treatment burden on patients with severe hemophilia A, 
non-replacement therapies, such as emicizumab, are becoming avail-
able, offering less frequent subcutaneous infusions for prophylaxis.7 
Non-replacement therapies have the potential to convert a severe 
bleeding phenotype into a non-severe bleeding phenotype with a more 
continuous pharmacodynamics profile and infrequent, on demand re-
quirement for FVIII replacement. When used in previously untreated 
patients (PUPs) with severe hemophilia A, it is anticipated that non-re-
placement therapies will reduce the bleeding frequency and subsequent 
FVIII administration, thus postponing initial FVIII exposure.
Data on the treatment history of patients with non-severe he-
mophilia A could provide important information about the expected 
bleeding phenotype and time course to treatment in PUPs with severe 
hemophilia A when treated with such novel therapies from a very early 
age onward. Unfortunately, the bleeding phenotype of patients with 
non-severe hemophilia A is not well known, as previous studies on this 
topic are limited by their cross-sectional and single-center designs and/
or by the inclusion of a selected patient cohort.8-11
Therefore, the aim of this study is to investigate the treatment his-
tory of patients with non-severe hemophilia A in a large, international, 
and multi-center non-severe hemophilia A cohort (the INSIGHT cohort). 
This study will focus on the age at the first FVIII exposure, the time in-
terval until the first 20 FVIII exposures, and the annual bleeding rate, 
stratified for subgroups of patients based on their residual FVIII level.
2  | METHODS
2.1 | Patients and setting
Patients were included from the INSIGHT study—a cohort of pa-
tients with non-severe hemophilia A (FVIII activity 2-40 IU/dL) who 
received at least one exposure to FVIII concentrate between 1980 
and 2011 in 1 of the 34 participating hemophilia treatment cent-
ers. For the present study we analyzed all patients born after the 1 
at first 20 EDs, annualized bleeding rate for all bleeds (ABR), joint bleeds (AJBR), and 
major spontaneous bleeds (ASmBR).
Results: In the total cohort (n = 1013), median baseline FVIII activity was 8 IU/dL (inter-
quartile range [IQR] 4-15) and the median age at ED1 was 3.7 years (IQR 1.4-7.7). Median 
age at ED1 rose from 2.5 years (IQR 1.2-5.7) in patients with FVIII:C 2-5 IU/dL to 9.7 years 
(IQR 4.8-16.0) in patients with FVIII:C 25-40 IU/dL. In the subgroup (n = 104), median 
age at ED1, ED5, ED10, and ED20 was 4.0 years (IQR 1.4-7.6), 5.6 years (IQR 2.9-9.3), 
7.5 years (IQR 4.4-11.3), and 10.2 years (IQR 6.5-14.2), respectively. Median ABR, AJBR, 
and ASmBR were 1.1 (IQR 0.5-2.6), 0.3 (IQR 0.1-0.7), and 0 (IQR 0-0), respectively.
Conclusion: This study demonstrates that in non-severe hemophilia A, the age at first 
FVIII exposure increases with baseline FVIII:C and that major spontaneous bleeds 
rarely occur.
K E Y W O R D S
factor VIII, hemophilia A, hemorrhage, joint bleed, treatment
Essentials
• Patients with non-severe hemophilia A (HA) receive fac-
tor VIII (FVIII) treatment on demand.
• Timing of FVIII treatment was assessed in a large inter-
national non-severe HA cohort.
• In non-severe HA, the median age at first FVIII exposure 
was 3.7 years.
• Patients with non-severe HA reached their 20th FVIII 
exposure at a median age of 10.2 years.
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January 1980. As FVIII concentrates were not widely available be-
fore 1980, patients born before this time point had delayed access to 
treatment with FVIII concentrates, which would bias the age at the 
first exposure to FVIII concentrates to a later time point. The follow-
up for all patients was from birth until either the end of the study, 
emigration, loss to follow-up, or death. We refer to previously pub-
lished papers for further information on the INSIGHT cohort.12-15
2.2 | Data collection
In the total INSIGHT cohort, the following clinical baseline charac-
teristics were available: baseline FVIII activity, date of the first FVIII 
exposure, the reason for the first FVIII treatment, total number of 
FVIII exposure days (EDs) during follow-up, F8 genotype, ethnicity, 
and family history of hemophilia A. Baseline FVIII activity was de-
fined as the lowest FVIII activity during follow-up. The definitions 
of a clinically relevant inhibitor development and an ED to FVIII con-
centrate are described in the supplemental list of definitions in sup-
porting information.
In the subgroup of the INSIGHT cohort, detailed information 
per ED was available. The subgroup consists of patients who de-
veloped inhibitors (24%) and their matched controls (76%; matched 
for age, exposure days, and hemophilia treatment center or coun-
try). In the subgroup, detailed clinical data for all FVIII exposures 
during follow-up until inhibitor development were available, in-
cluding: the calendar date of the ED and the reason for treatment 
(including type, location, and cause of the bleed or type of surgical 
procedure).
All bleeds that were treated with FVIII concentrate were in-
cluded in the analysis. Bleeds were classified as spontaneous if 
there were no provoking factors (sport activity or trauma) in the 
preceding 72 hours. Major bleeding events were defined as bleeds 
that occurred intracranially, in muscles, or in major joints (elbow, 
hip, knee, ankle) and required more than 1 ED to FVIII concentrate 
to resolve. The nature of spontaneous major bleeding episodes 
was verified by sending all investigators a verification list con-
taining the spontaneous bleeding episodes on file of patients that 
were treated in their center. Unverified bleeds remained classified 
as spontaneous.
The definitions for new bleeds were taken from the standard 
criteria defined by the Subcommittee on Factor VIII, Factor IX and 
Rare Coagulation Disorders of the Scientific and Standardization 




The primary outcome of the study was the age at first exposure to 
FVIII treatment. We classified the reason for first FVIII treatment as: 
bleed, surgery, prophylaxis, or unknown. The age at the first FVIII 
treatment is presented for seven baseline FVIII activity categories: 
patients with moderate hemophilia A (FVIII:C 2 and 3-5 IU/dL) and 
patients with mild hemophilia A (FVIII:C 5-10, 10-15, 15-20, 20-25, 
and 25-40 IU/dL).
2.3.2 | Secondary outcomes
The following secondary outcomes were investigated in the sub-
group: (a) the age at the first 20 FVIII EDs, (b) the annualized bleed-
ing rate (ABR) for all treated bleeds, (c) ABR for spontaneous major 
treated bleeds (ASmBR), and (d) the annualized joint bleeding rate 
(AJBR) for all treated joint bleeds. The ABR, ASmBR, and AJBR were 
based on bleeds treated with FVIII concentrates. The age at the first 
20 EDs was investigated both for EDs with all treatment indications 
(bleed, surgery, prophylaxis, or unknown) and exclusively for EDs 
due to bleeding episodes.
The ABR was calculated as: (total number of treated bleeding ep-
isodes during follow-up/the follow-up period in days) x 365.25. In 
this analysis we excluded patients (N = 22) with a follow-up period 
of less than 180 days. The results of the secondary outcomes are 
presented for two baseline FVIII activity categories: patients with 
moderate hemophilia A (FVIII:C 2-5 IU/dL) and patients with mild 
hemophilia A (FVIII:C 5-40 IU/dL). It was not possible to divide pa-
tients into six categories as in the cohort study, due to the smaller 
population size of the subgroup.
2.3.3 | Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics, 
version 25 (IBM SPSS Statistics, Chicago, IL, USA). Continuous 
data were reported as median with interquartile range (IQR) and 
categorical data as frequencies with percentage. To evaluate the 
age at the first FVIII exposure, Kaplan-Meier cumulative incidence 
distributions were calculated for each of the six baseline FVIII ac-
tivity categories. To compare the median age at first FVIII treat-
ment among the six baseline FVIII activity categories, the Mann 
Whitney U test was performed. Cases with missing data in the 
primary and secondary outcomes were removed from analysis. 




In total, 1013 patients were included in the total cohort and 104 
of them were included in the subgroup (see flowchart of patients 
in Figure 1). The median baseline FVIII activity was 8 IU/dL (IQR 
4-15) and 6 IU/dL (IQR 4-11) for the total cohort and the subgroup, 
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respectively. The median age at the end of follow-up was 16 years 
(IQR 10-23) in the total cohort and 10 years (IQR 6-15) in the sub-
group. Additional baseline characteristics are described in Table S1.
3.2 | Age at the first exposure to FVIII treatment
The age at the first ED to FVIII concentrates was known in 873 
patients. The median age at the first ED was 2.5 years (IQR 
1.2-5.7) for patients with a baseline FVIII activity between 2 and 
5 IU/dL, increasing up to 9.7 years (IQR 4.8-16.0) for patients with 
a baseline FVIII activity between 25 and 40 IU/dL (Table 1 and 
Figure 2). In nearly all categories of baseline FVIII activity, the 
age at the first exposure to FVIII treatment occurred earlier in 
patients with a positive family history of hemophilia (Table 1). The 
reason for the first exposure to FVIII concentrates was known in 
81% of patients (817/1013), with the majority of patients (74%) 
receiving FVIII concentrates for treatment of a bleed. (Table S2). 
F I G U R E  1   Flowchart of patients included in the study
INSIGHT cohort 
N = 2709
Excluded n = 1,696 
1,695 patients born < 1980 
1 patient missing FVlll level 
Included in study cohort 
N = 1013
Excluded n = 909 
No detailed follow-up data 
Included in subgroup 
N = 104
Baseline FVIII:C, IU/dL







Moderate, 2-5 N = 292 2.5 (1.2-5.7) 2.0 (1.0-5.0) 3.4 (1.8-6.6)
 Moderate, in categories
2 N = 65 1.7 (1.1-5.0) 1.4 (0.9-2.5) 3.3 (1.4-6.9)
3-5 N = 227 2.8 (1.2-6.0) 2.4 (1.0-5.0) 3.4 (2.0-6.5)
Mild, 5-40 N = 581 4.4 (1.7-9.4) 3.9 (1.4-7.9) 6.5 (2.4-13.0)
Mild, in categories
5-10 N = 221 3.8 (1.4-7.5) 3.0 (1.2-5.7) 6.4 (2.7-10.8)
10-15 N = 149 4.2 (1.7-9.2) 3.3 (1.5-6.6) 7.2 (1.8-15.9)
15-20 N = 93 4.2 (1.7-8.9) 4.5 (2.3-11.0) 4.2 (1.4-8.9)
20-25 N = 57 4.3 (1.9-11.2) 3.3 (1.7-9.2) 6.1 (2.0-13.3)
25-40 N = 61 9.7 (4.8-16.0) 8.0 (3.9-15.2) 12.1 (6.5-19.0)
Total, 2-40 N = 873 3.7 (1.4-7.7) 3.1 (1.3-6.5) 5.2 (2.1-9.9)
Note: Values are given in medians and interquartile ranges (IQR).
Abbreviations: ED, exposure day; FH, family history of hemophilia; FVIII, factor VIII.
TA B L E  1   Age at first exposure to FVIII 
concentrates stratified for FVIII activity 
and for family history of hemophilia
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At the age of 4 years, 48% of patients in the cohort had not yet 
been exposed to FVIII concentrates. The proportion of untreated 
patients increased with higher baseline levels of FVIII (Table S3).
3.3 | Age at the first 20 exposures to 
FVIII treatment
In the subgroup, a total of 2824 EDs were recorded in 104 patients. 
The median number of EDs per patient was 20 (IQR 12-38). The me-
dian age was 4.0 years (IQR 1.4-7.6) at ED1, 5.6 years (IQR 2.9-9.3) 
at ED5, 7.5 years (IQR 4.4-11.3) at ED10, 8.9 years (IQR 4.9-12.1) at 
ED15, and 10.2 (IQR 6.5-14.2) at ED20 for all treatment indications. 
The timing of the first 20 FVIII EDs was similar when bleeding was 
selected as treatment indication.
In Table 2 the timing of the first 20 EDs is presented for the two 
FVIII activity categories.
3.4 | Annualized bleeding rate
During follow-up, a total of 710 bleeding episodes were treated in 
the subgroup. The median ABR for all treated bleeds was 1.1 (IQR 
0.5-2.6) and the AJBR was 0.3 (IQR 0.1-0.7). Patients with moderate 
hemophilia A (N = 36) experienced bleeds more frequently when 
compared to patients with mild hemophilia A (N = 46). For moderate 
and mild hemophilia A, the median ABR was 1.6 (IQR 0.6-3.5) and 
0.8 (IQR 0.3-2.5), respectively. Of the 33 major spontaneous bleeds 
that occurred in 23 patients, 11 bleeds could be verified to be indeed 
spontaneous (33%). The median ASmBR was 0 (IQR 0-0).
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Moderate, 2-5 N = 48 All 4.5 (1.4-7.5) 5.2 (3.2-9.4) 5.9 (3.8-10.7) 7.6 (3.8-11.2) 10.9 (4.9-14.2)
N = 41 Bleeds 3.2 (1.4-7.4) 4.8 (2.7-8.7) 5.1 (2.5-9.5) 5.2 (3.3-10.9) 9.1 (4.7-12.3)
Mild, 5-40 N = 56 All 3.8 (1.3-8.4) 5.7 (2.8-9.1) 8.6 (4.4-11.7) 9.0 (5.8-12.8) 9.6 (6.7-14.3)
N = 48 Bleeds 4.0 (2.2-8.8) 7.7 (3.9-12.5) 9.6 (5.8-14.6) 10.3 (7.3-14.2) 10.8 (8.5-15.5)
Total, 2-40 N = 104 All 4.0 (1.4-7.6) 5.6 (2.9-9.3) 7.5 (4.4-11.3) 8.9 (4.9-12.1) 10.2 (6.5-14.2)
N = 89 Bleeds 3.9 (1.5-7.6) 5.8 (3.5-11.0) 7.6 (4.3-12.0) 9.0 (4.9-13.0) 10.2 (7.1-13.0)
Note: Values are given in medians (interquartile ranges).
Abbreviation: ED, exposure day; FVIII, factor VIII.
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4  | DISCUSSION
4.1 | Age at the first exposure to FVIII treatment
In this multicenter cohort study among 1013 patients with non-se-
vere hemophilia A, we demonstrated that the median age at the first 
exposure to FVIII treatment increases with baseline FVIII activity. 
At first exposure, the median age was 2.5 years (IQR 1.2-5.7) and 
4.4 years (IQR 1.7-9.4) in moderate and mild patients, respectively.
These results are in line with a previous Dutch single-center study 
that included 195 patients with non-severe hemophilia A (baseline 
FVIII:C 1-40 IU/dL), demonstrating a median age of 2.9 years (IQR 
1.1-12.2) in moderates and a median age of 5.5 years (IQR 1.8-15.0) 
in mild patients.9
We were able to further stratify the timing of initial FVIII treat-
ment for baseline FVIII activity in patients with mild hemophilia A.
We demonstrated that patients with baseline FVIII activity cate-
gories from 10 to 15 IU/dL to 20 to 25 IU/dL received their first FVIII 
treatment at comparable median ages (4.2-4.3 years). Interestingly, 
patients with baseline FVIII activity between 25 and 40 IU/dl 
reached this milestone at a significantly older age (9.7 years, IQR 4.8-
16.0). Acknowledging the relatively small number of patients with 
baseline FVIII activity between 25 and 40 IU/dL, these results may 
be influenced by the use of desmopressin as hemostatic agent of 
choice with a greater likelihood of sufficient response and efficacy 
to cover bleeds or procedures without recourse to FVIII concentrate. 
Patients with a positive family history received their first exposure 
to FVIII at an earlier age than patients with a negative family history. 
This is in line with previous results that demonstrated an earlier age 
of diagnosis in non-severe hemophilia when a positive family history 
is present.9,17
4.2 | Longitudinal observations
Our descriptive data from the subgroup demonstrated that the age 
at each ED given for a bleed was higher in patients with mild hemo-
philia A when compared to patients with moderate hemophilia A.
Although we found that patients with mild hemophilia A were 
slightly younger at the first and the twentieth ED when compared 
to patients with moderate hemophilia A (median age of, respectively, 
3.8 and 4.5 years at ED1 and, respectively, 9.6 and 10.9 years at 
ED20), this difference was not statistically significant. To our knowl-
edge this is the first study to investigate the age at the first 20 expo-
sures to FVIII treatment in patients with non-severe hemophilia A.
The median ABR for all bleed types varied from 1.6 (IQR 0.6-3.5) 
in patients with moderate hemophilia A to 0.8 (IQR 0.3-2.5) in pa-
tients with mild hemophilia A. These results are in line with the pre-
vious studies which reported ABRs of 0.6 for all bleed types in mild 
hemophilia A, acknowledging the wide ranges (0-31) in the study by 
Aznar et al.4,8,10
When evaluating the incidence of joint bleeds, we found a median 
AJBR of 0.3 (IQR 0.1-0.7) for all patients included in the subgroup. 
Stratified for severity, the median AJBR was 0.5 (IQR 0.15-1.1) and 
0.1 (IQR 0.0-0.6) in patients with moderate and mild hemophilia A, 
respectively. Three recent studies evaluated the AJBR in non-severe 
hemophilia A.8,10,11 Although our results are comparable with two 
of these studies, they are considerably lower than in the study by 
Soucie et al,11 which reported a mean AJBR of 2.8 in patients with 
moderate hemophilia A (FVIII activity 2-5 IU/dL) and a mean AJBR 
of 0.97 in patients with baseline FVIII activity between 5 and 40 IU/
dL. This difference may be explained by the fact that the latter study 
collected data on joint bleeds through self-reporting at annual visits, 
which could have led to an overestimation of the AJBR.11
In line with previous observations in patients with non-severe 
hemophilia A, patients in our study rarely experienced spontaneous 
major bleeding episodes (median ABR 0, IQR 0.0-0.0).18
4.3 | Strengths and limitations of the study
The INSIGHT cohort is an international, multi-center study contain-
ing a large population of patients with moderate and mild hemophilia 
A. This allows further classification of FVIII activity, providing de-
tailed information in the broad range of FVIII activity levels among 
patients with mild hemophilia A.
However, when interpreting the results of our study, there are 
certain limitations that should be kept in mind. Although the pro-
portion of patients with moderate hemophilia A in our cohort is 
only slightly higher than in most cohorts, it is important to note that 
our patients may have a relatively more severe bleeding pheno-
type10,19,20 due to the inclusion criteria of the INSIGHT study, which 
required patients to have received at least one exposure to FVIII 
concentrate.13 Therefore, the patients with very mild phenotypes or 
a good response to desmopressin treatment were excluded. Thus, 
the results of the present study are not applicable to this group of 
patients.
In this regard, it is important to mention that in the present study 
no information was collected on the use of desmopressin in our pop-
ulation. As desmopressin is the first-choice treatment in non-severe 
hemophilia A when possible, it may be expected that a significant 
proportion of patients in our study were treated with desmopressin 
prior to FVIII concentrate. Therefore, the median age at first treat-
ment may be lower than the median age of 3.7 years reported in this 
study, although many countries would not expose children less than 
2 years of age to desmopressin.
We acknowledge the limitations of retrospective data collec-
tion, especially with respect to the differentiation between sponta-
neous and non-spontaneous bleeding episodes. Despite our efforts, 
we could not verify the nature of all major spontaneous bleeds. 
However, of the bleeds that we could verify, the majority was re-
coded as a traumatic bleed. Therefore, we expect that the ABR for 
major spontaneous bleeds may be overestimated in this study.
Another potential limitation is that the baseline FVIII activity 
value was determined in participating centers local laboratories 
rather than in a central laboratory. Significant variability may be 
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present among laboratories in performing FVIII:C assays, possi-
bly due to differences in reagents and assays as well as due to pa-
tient-related variables.21,22
4.4 | Clinical implications
More insight into the natural course of non-severe hemophilia A 
may provide us with valuable information to predict the treatment 
course of severe hemophilia A patients who are treated with pro-
phylactic non-replacement prophylaxis therapies. Compared with 
severe hemophilia A patients, who receive their first FVIII treatment 
at a median age of 10 to 12 months, our results suggest a consider-
able postponement of the age at first FVIII treatment when severe 
patients are converted to a non-severe bleeding phenotype.9,23,24
If the bleed and treatment profile in this non-severe hemophilia 
A cohort would be equivalent to severe hemophilia A receiving pro-
phylaxis with non-replacement therapy, the postponement of the 
first 20 exposures could have implications for inhibitor surveillance 
in patients with severe hemophilia A.
Currently, pediatric centers are very methodical in inhibitor surveil-
lance in the first 20 EDs through to 50 EDs, which happens within a 
relatively short time frame of months or only a couple of years after the 
first exposure.25 Our data presented here suggest this time period for 
inhibitor surveillance will be spread out over years rather than months 
for the majority in the context of a non-replacement prophylaxis agent. 
This would require important attention to detail and change in practice 
for continuity of care and inhibitor screening after each exposure.
In conclusion, this study on the treatment history of patients with 
non-severe hemophilia A demonstrates that the age at first exposure 
to FVIII treatment increases with baseline FVIII activity and suggests 
that these patients rarely experience major spontaneous bleeds. Our 
data may provide insight into the expected effect of non-replace-
ment therapies in patients with severe hemophilia A, suggesting a 
considerable postponement of the age at initial FVIII treatment.
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